Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion ...
The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...
The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at ...
(Reuters) -Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its COVID shot's ...
Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...
Investing.com -- Pfizer Inc. (NYSE: PFE) stock fell 1.5% following reports that U.S. prosecutors are investigating a claim ...
Robert F. Kennedy Jr. is set to significantly cut the size of HHS, reshaping the nation’s health agencies and closing ...
Citi analyst Geoff Meacham keeps a Neutral rating on Pfizer (PFE) with a $27 price target after the Wall Street Journal reported that U.S.
Read the exclusive report here. U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful ...
US Prosecutors Probe Tip About Timing of Pfizer's COVID Vaccine, WSJ Reports (Reuters) -Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its COVID shot's ...
The report said on Wednesday GSK's former head of vaccine development, Philip Dormitzer, had told his colleagues about the delay by Pfizer, where he worked before joining the British company.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results